Among patients with newly diagnosed (untreated) prostate cancer in this cohort, 62 of these patients had their TMPRSS2:ERG status determined using a urine TMPRSS2:ERG fusion assay (See Additional file 1: Data #1 for all patient data). This evidence concerns the gene TMPRSS2 and prostate carcinoma.